Literature DB >> 20802182

A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.

David E Hurtado1, Laura Molina-Porcel, Michiyo Iba, Awo K Aboagye, Steven M Paul, John Q Trojanowski, Virginia M-Y Lee.   

Abstract

Senile plaques formed by β-amyloid peptides (Aβ) and neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau, a microtubule-associated protein, are the hallmark lesions of Alzheimer's disease (AD) in addition to loss of neurons. While several transgenic (Tg) mouse models have recapitulated aspects of AD-like Aβ and tau pathologies, a spatiotemporal mapping paradigm for progressive NFT accumulation is urgently needed to stage disease progression in AD mouse models. Braak and co-workers developed an effective and widely used NFT staging paradigm for human AD brains. The creation of a Braak-like spatiotemporal staging scheme for tau pathology in mouse models would facilitate mechanistic studies of AD-like tau pathology. Such a scheme would also enhance the reproducibility of preclinical AD therapeutic studies. Thus, we developed a novel murine model of Aβ and tau pathologies and devised a spatiotemporal scheme to stage the emergence and accumulation of NFTs with advancing age. Notably, the development of NFTs followed a spatiotemporal Braak-like pattern similar to that observed in authentic AD. More significantly, the presence of Aβ accelerated NFT formation and enhanced tau amyloidosis; however, tau pathology did not have the same effect on Aβ pathology. This novel NFT staging scheme provides new insights into the mechanisms of tau pathobiology, and we speculate that this scheme will prove useful for other basic and translational studies of AD mouse models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20802182      PMCID: PMC2947292          DOI: 10.2353/ajpath.2010.100346

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model.

Authors:  John F Reilly; Dora Games; Russell E Rydel; Stephen Freedman; Dale Schenk; Warren G Young; John H Morrison; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

2.  Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons.

Authors:  Edward B Lee; Daniel M Skovronsky; Farhad Abtahian; Robert W Doms; Virginia M-Y Lee
Journal:  J Biol Chem       Date:  2002-12-11       Impact factor: 5.157

3.  Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils.

Authors:  J Götz; F Chen; J van Dorpe; R M Nitsch
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

4.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

5.  Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia.

Authors:  D R Thal; M Holzer; U Rüb; G Waldmann; S Günzel; D Zedlick; R Schober
Journal:  Exp Neurol       Date:  2000-05       Impact factor: 5.330

Review 6.  Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease.

Authors:  Yoo-Hun Suh; Frederic Checler
Journal:  Pharmacol Rev       Date:  2002-09       Impact factor: 25.468

7.  Design, power, and interpretation of studies in the standard murine model of ALS.

Authors:  Sean Scott; Janice E Kranz; Jeff Cole; John M Lincecum; Kenneth Thompson; Nancy Kelly; Alan Bostrom; Jill Theodoss; Bashar M Al-Nakhala; Fernando G Vieira; Jeyanthi Ramasubbu; James A Heywood
Journal:  Amyotroph Lateral Scler       Date:  2008

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease.

Authors:  Salvatore Oddo; Antonella Caccamo; Masashi Kitazawa; Bertrand P Tseng; Frank M LaFerla
Journal:  Neurobiol Aging       Date:  2003-12       Impact factor: 4.673

10.  Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology.

Authors:  Bärbel Schönheit; Rosemarie Zarski; Thomas G Ohm
Journal:  Neurobiol Aging       Date:  2004-07       Impact factor: 4.673

View more
  82 in total

1.  Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.

Authors:  David E Hurtado; Laura Molina-Porcel; Jenna C Carroll; Caryn Macdonald; Awo K Aboagye; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

2.  The acetylation of tau inhibits its function and promotes pathological tau aggregation.

Authors:  Todd J Cohen; Jing L Guo; David E Hurtado; Linda K Kwong; Ian P Mills; John Q Trojanowski; Virginia M Y Lee
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

3.  Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo.

Authors:  Sarah L DeVos; Bianca T Corjuc; Caitlin Commins; Simon Dujardin; Riley N Bannon; Diana Corjuc; Benjamin D Moore; Rachel E Bennett; Mehdi Jorfi; Jose A Gonzales; Patrick M Dooley; Allyson D Roe; Rose Pitstick; Daniel Irimia; Matthew P Frosch; George A Carlson; Bradley T Hyman
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

4.  Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage.

Authors:  Yohei Shibuya; Zhaoyang Niu; Elena Y Bryleva; Brent T Harris; Stephanie R Murphy; Alireza Kheirollah; Zachary D Bowen; Catherine C Y Chang; Ta-Yuan Chang
Journal:  Neurobiol Aging       Date:  2015-04-07       Impact factor: 4.673

5.  Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections.

Authors:  Michiyo Iba; Jennifer D McBride; Jing L Guo; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee
Journal:  Acta Neuropathol       Date:  2015-07-07       Impact factor: 17.088

6.  Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities.

Authors:  Hien T Tran; Frank M LaFerla; David M Holtzman; David L Brody
Journal:  J Neurosci       Date:  2011-06-29       Impact factor: 6.167

7.  CD47 does not mediate amyloid-β(1-42) protofibril-stimulated microglial cytokine release.

Authors:  Sanjib Karki; Michael R Nichols
Journal:  Biochem Biophys Res Commun       Date:  2014-10-22       Impact factor: 3.575

Review 8.  Three dimensions of the amyloid hypothesis: time, space and 'wingmen'.

Authors:  Erik S Musiek; David M Holtzman
Journal:  Nat Neurosci       Date:  2015-06       Impact factor: 24.884

9.  Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy.

Authors:  Michiyo Iba; Jing L Guo; Jennifer D McBride; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2013-01-16       Impact factor: 6.167

10.  A unique tau conformation generated by an acetylation-mimic substitution modulates P301S-dependent tau pathology and hyperphosphorylation.

Authors:  Deepa Ajit; Hanna Trzeciakiewicz; Jui-Heng Tseng; Connor M Wander; Youjun Chen; Aditi Ajit; Diamond P King; Todd J Cohen
Journal:  J Biol Chem       Date:  2019-09-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.